Propagenix is a preclinical-stage platform technology company that is applying its unique technology to both internal and partnered cell therapy programs. The company is engaged in the development and commercialization of technology which originated from the laboratory of Dr. Richard Schlegel of Georgetown University.
PLEXOVAL Exosome Wound Healing Human Study Starts
-
A world-first study using cell free exosome product manufactured using Exopharm’s LEAP Technology
-
Study sites at the Royal Melbourne Hospital and Australian Red Cross Blood Service
-
Results by mid 2020
26 August 2019, Melbourne, Australia: Regenerative medicine company Exopharm Limited (ASX:EX1) announces the start of the PLEXOVAL Phase 1 study, the first human clinical trial using exosomes for wound healing. [Read more…]
Market Forces Driving Growth of the Exosome Industry
Market forces driving growth of the exosome have been expanding over the past two years, with increasing investment flowing into the space, merger and acquisition (M&A) activity accelerating, and new therapeutics entering various stages of development. Exosomes are defined as small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. They are made in some form by all species, including bacteria that produce analogous outer membrane vesicles (OMC). [Read more…]
denovoMATRIX Introduces Ready-to-use, Chemically Defined Coated Cell Cultureware for Serum-free hMSC Expansion
August 22, 2019, Dresden, Germany — Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells (hMSC) offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment. [Read more…]
Nucleus Biologics acquires Primorigen Biosciences, gains proprietary, high yield, recombinant protein platform
SAN DIEGO, Aug. 6, 2019 — Nucleus Biologics, a leader in precision cell culture, is pleased to announce the acquisition of Primorigen Biosciences, Inc. The addition of Primorigen’s Vitronectin XF™ and platform recombinant protein production technology will play a huge role in Nucleus’ strategy of offering traceable, reproducible and xeno-free (XF) cell culture ecosystems for the cell and gene therapy space. [Read more…]
- « Previous Page
- 1
- …
- 208
- 209
- 210
- 211
- 212
- …
- 338
- Next Page »




